Skip to main content
S&P 5007,707.05+1.82%DOW53,349.37+3.02%NASDAQ25,864.56+1.94%BTC$80,298.00+3.66%ETH$2,426.37+6.08%GOLD$4,070.70+3.31%OIL$88.10-8.32%
Smart Investors Daily
SID Premium
NN

AMEX · NNVC

NanoViricides, Inc.

Healthcare · Biotechnology

$1.43

Down-$0.03 (-2.10%)

Updated Nov 4, 2026, 4:10 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.05M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.87 – $1.93
Volume
160.49K
Avg. volume
305.78K

Price performance · NNVC

NNVC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

NNVC closed at $1.43 after 21 trading sessions, up 2.14% for the selected period.

Last close
$1.43
Period change
+2.14%
Period low
$1.28
Period high
$1.51
Daily close
View OHLC price history
NNVC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.36$1.456$1.36$1.43160.49K
Nov 2, 2026$1.35$1.39$1.34$1.3577.74K
Oct 30, 2026$1.41$1.45$1.33$1.33224.3K
Oct 29, 2026$1.41$1.4763$1.41$1.4372.81K
Oct 28, 2026$1.44$1.495$1.44$1.4583.5K
Oct 27, 2026$1.48$1.50$1.4007$1.46237.39K
Oct 26, 2026$1.38$1.40$1.32$1.36220.95K
Oct 23, 2026$1.35$1.47$1.3301$1.40159.57K
Oct 22, 2026$1.46$1.53$1.38$1.39147.33K
Oct 21, 2026$1.47$1.52$1.415$1.51206.64K
Oct 20, 2026$1.30$1.51$1.30$1.48464.1K
Oct 19, 2026$1.37$1.39$1.30$1.30161.72K
Oct 16, 2026$1.36$1.40$1.34$1.38154.89K
Oct 15, 2026$1.30$1.40$1.30$1.37200.71K
Oct 14, 2026$1.32$1.34$1.28$1.31157.72K
Oct 13, 2026$1.24$1.34$1.24$1.32240.13K
Oct 12, 2026$1.31$1.3299$1.27$1.28133.01K
Oct 9, 2026$1.33$1.4042$1.30$1.30169.63K
Oct 8, 2026$1.38$1.415$1.30$1.31299.63K
Oct 7, 2026$1.43$1.50$1.4001$1.44306.21K
Oct 6, 2026$1.45$1.48$1.36$1.40303.31K

Latest NNVC news

The latest Smart Investors Daily articles mentioning NNVC.

Stock researchCompany · Overview

NNVC research

Overview

Company profile and research snapshot.

Company profile

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NNVC recent ratings
DateFirmRatingTarget
Jul 6, 2026Noble Capital MarketsOutperform—
May 7, 2024EF HuttonBuy—
Feb 16, 2024EF HuttonBuy—
Apr 18, 2023EF HuttonBuy—
Feb 28, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

SHELTON, CT / ACCESS Newswire / October 27, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, explained today that the Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the Phase IIB clinical trial part as soon as the Phase IIA part is completed.

Yahoo · Oct 20, 2026

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact ChildrenSHELTON, CT / ACCESS Newswire / October 20, 2026 / , Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that its broad-spectrum antiviral drug NV-387 has succ

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By